Abstract 459P
Background
With cancer as the leading cause of death in Korea and globally, addressing non-cancer mortality, specifically cardiovascular disease, is critical. Dyslipidemia, a significant risk factor for cardiovascular disease, requires proper management in cancer survivors. This study aims to analyze factors associated with undertreatment of dyslipidemia in cancer survivors and investigate the impact of the National Health Screening Program (NHSP) on undertreatment in Korea.
Methods
This cross-sectional study analyzed data from the Korea National Health and Nutrition Survey (KNHANES) conducted between 2007 and 2019. It included 2,226 participants (792 males, 1,434 females) aged 40-75 who had a history of cancer. Self-reported questionnaires collected information following the 2018 Cholesterol Treatment Guidelines by the American College of Cardiology/American Heart Association. Multiple logistic regression analysis with integrated weights was performed.
Results
Among cancer survivors, 16.3% received treatment for dyslipidemia. Of those who were untreated, 46.64% had normal blood lipid levels, while 37.0% were not receiving adequate treatment. Additionally, 72.7% of cancer survivors participated in the NHSP, and the undertreatment rate for dyslipidemia was significantly lower in the screened group compared to the non-screened group (34.14% vs. 44.78%; P < 0.001). Adjusting for age and sex, cancer survivors in the non-screened group had a significantly higher risk of not receiving appropriate dyslipidemia treatment (odds ratio [OR] 1.47, 95% confidence interval [CI] 1.10, 1.97). Even after considering socioeconomic and cancer-related factors, the non-screened group remained significantly associated with undertreatment of dyslipidemia (OR 1.36, 95% CI: 1.02, 1.82), especially among female cancer survivors (OR 1.49, 95% CI: 1.05, 2.14).
Conclusions
This study is the first to assess the association between NHSP and undertreatment of dyslipidemia. Encouraging cancer survivors to participate in the NHSP would be an effective strategy to reduce the incidence and mortality of concurrent cardiovascular disease, ultimately improving the overall health of cancer survivors.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
111P - Comparison of the efficacy and safety of fruquintinib and fruquintinib combined with immune checkpoint inhibitors in the treatment of metastatic microsatellite stable colorectal cancer: A real-world study
Presenter: Zhiqiang Wang
Session: Poster Display
Resources:
Abstract
112P - Optimal classification and treatment strategy based on technical and oncological futures in recurrence of colorectal liver metastases
Presenter: Kosuke Kobayashi
Session: Poster Display
Resources:
Abstract
113P - Phase I/II study of capecitabine(C)/oxaliplatin(O)/irinotecan(I) combined with bevacizumab(B) in the first-line treatment of metastatic colorectal cancer (mCRC)
Presenter: Kai Ou
Session: Poster Display
Resources:
Abstract
114P - The prognostic role of LAG-3 expression in metastatic colorectal cancer
Presenter: Yi-Hsuan Huang
Session: Poster Display
Resources:
Abstract
115P - Sidedness and survival of chemo-refractory metastatic colorectal cancer treated with lonsurf or regorafenib: A nationwide population-based study in Taiwan
Presenter: Meng-Che Hsieh
Session: Poster Display
Resources:
Abstract
116P - Burden and trends of colorectal cancer in high income Asia Pacific countries from 1990-2019 and its projections of deaths to 2040: A comparative analysis
Presenter: Monika Chhayani
Session: Poster Display
Resources:
Abstract
117P - Australasian real-world treatment selection and clinical outcomes for patients with left side (LS), RAS wildtype (RASwt) metastatic colorectal cancer (mCRC)
Presenter: Vanessa Wong
Session: Poster Display
Resources:
Abstract
119P - Neoadjuvant chemoradiotherapy in the mode of hypofractionation in locally advanced rectal cancer: Is it time to change standards of care?
Presenter: Abror Abdujapparov
Session: Poster Display
Resources:
Abstract
120P - Improved clinical outcomes with cetuximab maintenance therapy in left-sided RAS/BRAF wild-type metastatic colorectal cancer: A real-world study of Hunan cancer hospital
Presenter: Xiaolin Yang
Session: Poster Display
Resources:
Abstract
121P - Single-cell sequencing reveals the role of Treg cells with high expression of BIRC3 in regulating the progression of colorectal cancer
Presenter: Yuqiu Xu
Session: Poster Display
Resources:
Abstract